ArticleCureus2026
Biological Profile of Dysmyelopoiesis in Bone Marrow Aspirates at the Joseph Ravoahangy Andrianavalona University Hospital, Madagascar.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Dysmyelopoiesis refers to morphological abnormalities affecting bone marrow cells and may arise in both reactive and malignant conditions. Its interpretation can sometimes be challenging, particularly in settings where access to advanced diagnostic tools is limited. The present study aimed to describe the biological characteristics of dysmyelopoiesis observed in bone marrow aspirates. Methods A retrospective descriptive cross-sectional study was conducted at the hematology laboratory of the Joseph Ravoahangy Andrianavalona University Hospital in Antananarivo, Madagascar, over a three-year period from April 2020 to March 2023. Bone marrow smears showing dysplastic features involving at least 10% of cells in one or more hematopoietic lineages were included. Results During the study period, 1006 bone marrow examinations were performed, among which 71 cases of dysmyelopoiesis were identified, corresponding to a frequency of 7.06%. Hematological abnormalities were mainly represented by anemia in 55 cases (77.46%), thrombocytopenia in 51 cases (71.83%), and leukopenia in 33 cases (46.48%). Bone marrow cellularity was predominantly normocellular or hypercellular. Dysplasia involved a single lineage in 24 cases (33.80%), whereas multilineage involvement was observed in 31 cases (43.66%). Megakaryocytic abnormalities were mainly characterized by small-sized megakaryocytes in 19 cases (26.76%) and hypolobulated nuclei in 8 cases (11.27%). In the granulocytic lineage, hypogranulation and nuclear hyposegmentation were identified in 26 cases (36.62%) and 18 cases (25.35%), respectively. Erythroid dysplasia was predominantly marked by nuclear budding in 28 cases (39.44%) and laminated cytoplasm in 27 cases (38.03%). Based on the available clinical and laboratory data, dysmyelopoiesis was considered reactive in 18 cases (22.53%) and suggestive of a malignant process in 53 cases (77.46%). Conclusion The coexistence of reactive and malignant dysmyelopoietic features highlights the diagnostic complexity of dysmyelopoiesis. Accurate interpretation requires integration of clinical and biological findings and a multidisciplinary approach to guide patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.